Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...

Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...

From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...

Cellular therapy, a revolutionary approach where cells are manipulated outside the body and then reintroduced to treat or prevent diseases, has been recognized in recent years as a highly promising ...

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novavax, Inc. ("Novavax" or "the Company") . Investors who purchased Novavax securities are encouraged ...

have announced new results from a Phase II clinical study evaluating the investigational combination of islatravir, an ...

The 1) Market is expected to reach a substantial USD 34.83 billion by 2033, according to a new report. This reflects a ...

TD Cowen analyst Tyler Van Buren has maintained their bullish stance on GILD stock, giving a Buy rating today. Tyler Van Buren’s rating ...

"We are essentially moving from a situation of defeating the enemy in all the contact villages to a state of destruction." Information ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

Drone commander admits the military goals have changed but insists the West must stay strong in its support of Kyiv ...